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Abstract
Background and aims: Current endoscopic activity scores for ulcerative colitis (UC) do not take 
into account the extent of mucosal inflammation. We have developed a simple endoscopic index 
for UC that takes into account the severity and distribution of mucosal inflammation.
Methods: In this multicentre trial, UC patients undergoing colonoscopy were prospectively 
enrolled. For the Modified Score (MS), the sum of Mayo Endoscopic Subscores (MESs) for five 
colon segments (ascending, transverse, descending, sigmoid and rectum) was calculated. The 
Extended Modified Score (EMS) was obtained by multiplying the MS by the maximal extent of 
inflammation. The Modified Mayo Endoscopic Score (MMES) was obtained by dividing the EMS 
by the number of segments with active inflammation. Colon biopsies were obtained from the 
rectum and sigmoid, as well as from all inflamed segments, by standard methods. Clinical activity 
was scored according to the Partial Mayo Score (PMS). Biological activity was scored according 
to C-reactive protein (CRP) and faecal calprotectin (FC) levels. Histological activity was scored 
according to the Geboes Score (GS).
Results: One hundred and seventy-one UC patients (38% female, median age 47 years, median 
disease duration 13  years) were included. The MMES correlated significantly with the PMS 
(r = 0.535), CRP (r = 0.238), FC (r = 0.730) and GS (r = 0.615) (all p < 0.001). Median MMES scores 
were significantly higher in patients with clinical, biological or histological activity (all p ≤ 0.001)
Conclusions: The MMES is an easy to use endoscopic index for UC that combines the severity 
analysis of the MES with disease extent, and correlates very well with clinical, biological and 
histological disease activity.
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Modified Mayo Endoscopic Score 847
1. Introduction
Mucosal healing (MH) has become an important goal in the treat-
ment of ulcerative colitis (UC). The presence of MH has been dem-
onstrated to decrease the risk of relapse, hospitalizations, colorectal 
cancer and colectomy.1–5 Recently, endoscopic assessment has been 
demonstrated to be a feasible and more beneficial strategy than 
clinical assessment to guide treatment optimization in UC patients.6 
However, there are several limitations with an endoscopy-based 
approach to treatment. Firstly, many different endoscopic scores 
exist. Moreover, no validated definition of MH currently exists in 
the literature. Although different endoscopic scores have been used 
to define MH,7–13 the Mayo endoscopic subscore (MES) of 0 or 1 
has been one of the most used definitions.2,14–22 Secondly, patients 
may present with patchy healing (especially those on topical treat-
ment); however, at present there are no data on the outcomes of this 
partial MH.
The first endoscopic scores were developed to assess the severity 
but not the extent of endoscopic activity in ulcerative colitis. These 
include the Baron score,23 the Powell–Tuck index,24 the MES,25 the 
Sutherland index26 and the Rachmilewitz index,27 most of them shar-
ing similar endoscopic variables.
In the Baron score (four-point scale),23 the Powel–Tuck index 
(Saint Mark’s index, three-point scale)24 and the endoscopic sub-
score of the Sutherland index (UC disease activity index, four-point 
scale),26 the degree of endoscopic disease activity is mainly based on 
the severity of mucosal friability and bleeding, while the presence of 
mucosal ulcerations is not included. In contrast, the modified Baron 
score (five-point scale)28 and the Rachmilewitz endoscopic index 
(12-point scale)27 were developed to incorporate the vascular pat-
tern, as well as the presence of granularity, hyperaemia, friability, 
bleeding and ulcerations.
The MES (four-point scale) was developed in 1987 by Schroeder 
et al.25 Partly due to its simplicity, the MES is the most commonly 
used endoscopic activity index in clinical trials for evaluating treat-
ment efficacy in terms of endoscopic improvement.
None of the aforementioned endoscopic scores has been 
validated.
Recently, the Ulcerative Colitis Endoscopic Index of Severity 
(UCEIS, nine-point scale) has been developed based on the intra- 
and inter-observer variability of 10 endoscopic descriptors.29 This 
index grades three endoscopic findings, namely vascular pattern, 
bleeding and erosions/ulcers, into different levels of severity with 
precise definitions. The UCEIS, as well as the previous endoscopic 
scores, is based on the macroscopic evaluation of the most severely 
involved colon segment and does not take into account the extent of 
UC involvement.
So far, the only endoscopic index taking into account all the 
colonic segments is the Ulcerative Colitis Colonoscopic Index of 
Severity (UCCIS), developed in 2013 by Samuel et al.30 This index is 
calculated by a formula that includes four different variables (gran-
ularity, vascular pattern, ulceration and bleeding–friability), all of 
them scored in each of the five segments (rectum, sigmoid, descend-
ing, transverse and ascending). It has been validated by rigorous 
methodology and it has high inter-observer agreement. However, its 
feasibility and simplicity of use need to be demonstrated in clini-
cal practice. Moreover, the UCCIS was not correlated to histological 
activity.
The MES is still the best known and most extensively used endo-
scopic index both in clinical trials and in clinical practice. Our aim 
was to develop a simple score for UC endoscopic activity, taking 
into account the severity and distribution of mucosal inflammation 
based upon the widely used MES. As secondary objectives, we aimed 
to correlate this new endoscopic score with clinical, biological and 
histological activity.
2. Methods
2.1. Patient population
This was a prospective longitudinal study in two tertiary referral 
hospitals: the University Hospitals Leuven (Leuven, Belgium) and 
McGill University Health Centre (Montreal, Canada). We included 
adult UC patients diagnosed according to conventional endoscopic, 
radiological and histological criteria31 who underwent colonoscopy 
or sigmoidoscopy as part of routine clinical care between December 
2012 and March 2014. Patients were allowed to take any UC treat-
ment, including mesalamine, steroids, immunosuppressants, biologi-
cals and all investigational agents. All patients gave written informed 
consent. The study was approved of by the local ethics committees 
of the centres in Belgium (ML8655) and in Canada (12-392-GEN).
Subjects with a history of (sub)total colectomy or those in whom 
the upper limit of colonic inflammation was not reached during 
endoscopy were excluded.
2.2. Clinical activity
Clinical activity was scored on the same day as endoscopy accord-
ing to the Partial Mayo Score (PMS). Symptomatic remission was 
defined as a Mayo stool frequency subscore of 0 or 1 and a Mayo 
rectal bleeding subscore of 0.2
2.3. Biological activity
A blood analysis was obtained on the day of colonoscopy, including the 
determination of haemoglobin, leucocytes, platelets, C-reactive protein 
(CRP) and albumin. A  stool sample that was obtained immediately 
before bowel preparation was provided by each patient for the analysis 
of faecal calprotectin (FC). The FC level was measured with the Quantum 
Blue kit (Bühlmann, Schonenbuch, Switzerland). A CRP <5 mg/L and a 
FC <250 µg/g32,33 were considered to indicate inactive disease.
2.4. Endoscopic activity
During endoscopy, the operator scored the visualized colon for 
UC activity using the provided Modified Mayo Endoscopic Score 
(MMES) scoring sheet (Table 1). The colon was divided into five seg-
ments (ascending, transverse, descending colon, sigmoid and rectum) 
and for each segment the operator assessed the MES. The opera-
tor also reported the maximal extent of inflammation at the time of 
colonoscopy. The sum of individual MESs of all segments was cal-
culated to obtain the Modified Score (MS) on a 15-point scale. The 
Extended Modified Score (EMS) was then obtained by multiplying 
the MS by disease extent in decimetres. The MMES was obtained by 
dividing the EMS by the number of segments with active inflamma-
tion. A caecal patch and pseudopolyps were not regarded as repre-
senting inflammation. See example in (Table 1).
2.5. Histological activity
Colonic biopsies were obtained from the rectum and at 25 cm in all 
patients and additionally at all macroscopically inflamed segments.
Histological activity was scored according to the Geboes Score 
(GS). This is a comprehensive grading system that evaluates for 
the presence of architectural changes, mononuclear cells, eosino-
phils, neutrophils, crypt destruction and erosions or ulcerations 
(Supplementary Table 1).34 Active histological activity was defined as 
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GS ≥3.1 (presence of neutrophils in the epithelium).35 One additional 
parameter, basal plasmacytosis, was also evaluated.35
Because multiple biopsies were obtained, the biopsy with the 
highest GS was the one included in the analysis.
2.6. Statistical analyses
We used SPSS Version 19.0 (SPSS, Chicago, Illinois, USA) for appropri-
ate statistical methods. Descriptive statistics were calculated as percent-
ages for discrete data and medians with interquartile ranges (IQRs) 
for continuous data. Spearman correlations between the endoscopic 
activity scores and histological activity scores, the PMS, albumin, CRP 
level and FC were calculated. Significance was accepted at p < 0.05.
3. Results
3.1. Patient characteristics
The patients’ characteristics are summarized in Table  2. A  total 
of 171 patients were included (76 from McGill University Health 
Centre in Montreal and 95 from University Hospitals Leuven). 
Forty-two out of the 171 patients underwent incomplete colonosco-
pies; all 42 were patients with known distal UC in whom the upper 
limit of endoscopic inflammation was reached.
3.2. Correlation analysis
Spearman’s correlations among clinical, biological, endoscopic and 
histological activity are shown in Table 3. The histological activity 
and FC correlated best with the endoscopic scores, followed by clini-
cal activity. In contrast, the correlation between CRP and endoscopic 
activity was poor regardless of endoscopic score.
3.3. Clinical, biological and histological variables 
and MMES
The median MMES scores were significantly higher among patients 
with clinical, biological and histological activity compared with 
patients in clinical, biological and histological remission (Figure 1). 
Interestingly, median FC level was proportional to MMES grade 
(Figure 2). However, in the multivariate analysis, after adjusting for 
the extent and severity of endoscopic activity only the severity of 
endoscopic activity defined by MES remained as an independent risk 
factor for FC ≥250 (µg/g) [odds ratio (OR) 2.25, 95% confidence 
interval (CI) 1.42–3.57; p = 0.001]. Similar results were obtained for 
the MS (OR 1.78, 95% CI 1.41–2.24; p < 0.001).
3.4. MMES and MES
As expected, MMES medians (IQR) were different for the four 
grades of MES (Figure 3). Different grades of MMES were reported 
for each grade of MES considering the extent of endoscopic activity, 
demonstrating the added information provided by MMES compared 
with MES.
3.5. Prediction of active histological activity by 
MMES
Active histological activity (GS ≥3.1) was predicted by MMES 
>0.8 with 74% sensitivity and 79% specificity. The area under the 
curve (AUC) was 0.79 (95% CI 0.72–0.96; p < 0.001) (Figure 4). 
Similarly, MMES >0.8 predicted the presence of basal plasmacyto-
sis with 83% sensitivity and 79% specificity (AUC 0.85, 95% CI 
0.79–0.91; p < 0.001)
4. Discussion
This study assessed the MMES, a newly developed endoscopic score 
for UC, taking into account the total endoscopic mucosal disease 
extent. The score can be easily calculated by assessing the commonly 
used MES for five colonic segments and the total extent of mucosal 
inflammation. We have shown that MMES correlates well with 
Table 1. Example of calculation of the Modified Mayo Endoscopic 
Score (MMES).
Colonic segments Evaluated1  
(0 or 1)
Inflamed2  
(0 or 1)
MES3 
(0–3)
Rectum 1 1 3
Sigmoid 1 1 2
Descending colon 1 1 2
Transverse colon 1 0 0
Ascending colon 1 0 0
Total (= Mayo score) 5 3 7
Maximal extent (dm)a = 5.
Mayo score = 3.
Modified Score (sum of MES values) = 7.
Extended Modified Score (EMS; MS × maximum extent) = 7 × 5 = 35.
Mayo Modified Endoscopic Score
(EMS/no. of segments with Mayo Endoscopic Subscore > 0) = 35/3 = 11.7
1Evaluated: 1 if this segment was (completely or partly) evaluated.
2Inflamed: 1 if Mayo Endoscopic Subscore for this segment was not 0.
3Mayo Endoscopic Subscore: evaluated for the macroscopically most 
severely inflamed part; score 0 for a segment with normal or inactive disease; 
score 1 for a segment with erythema, decreased vascular pattern, mild fri-
ability; score 2 for a segment with marked erythema, absent vascular pattern, 
friability, erosions; score 3 for a segment with ulcerations or spontaneous 
bleeding.
aMaximal extent: measured in decimetres during withdrawal.
Table 2. Patient characteristics (n = 171).
Female (%) 65 (38)
Age (years), median (IQR) 47 (34–56)
Disease duration (years), median (IQR) 13 (6–20)
UC extension: E1/E2/E31 (%) 23/68/66 (15/43/42)
Medication at the time of endoscopy (%)
Mesalamine 113 (66)
Corticosteroids 13 (8)
Immunosuppressive therapy2 32 (19)
Anti-tumour necrosis factor 44 (26)
Partial Mayo Score, median (IQR) 0 (0–2)
C-reactive protein (mg/L), median (IQR) 1.9 (0.5–5.8)
Haemoglobin (g/dL), median (IQR) 14.2 (13.2–15.1)
White blood cells (109/L) (IQR), median (IQR) 6.5 (5.2–8.4)
Platelets (109/L), median (IQR) 245.5 (207–304)
Albumin (g/L), median (IQR) 4 (40.2–45.2)
Faecal calprotectin (µg/g), median (IQR) 118 (100–486)
Disease extent (dm), median (IQR) 0.5 (0–3.5)
Mayo Endoscopic Subscore, median (IQR) 1 (0–2)
Modified Score, median (IQR) 1 (0–3)
Extended Modified Score, median (IQR) 1 (0–11)
Modified Mayo Endoscopic Score, median (IQR) 0.6 (0–5.3)
Patients with Geboes Score ≥3.1 (%) 75 (48)
Patients with diffuse/focal basal  
plasmacytosis (%)
36/34 (22/21)
IQR, interquartile range.
1UC extent according to Montréal classification: E1, proctitis; E2, left-
sided colitis; E3, extensive colitis. 2Azathioprine, 6-mercaptopurine, metho-
trexate, tacrolimus.
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clinical, biological and histological variables of disease activity. The 
main advantage of the MMES is the fact that it takes into account 
disease extent and makes it possible to assess partial mucosal heal-
ing, which may influence patient management
Despite the development of many different endoscopic scores 
for UC,23,24,26–28 the MES25 remains the most commonly used one, 
because of its easy calculation and its use in both clinical practice 
and clinical trials. However, this score does not take into account 
the extent of endoscopic activity, which changes during both the 
natural and the treated course of a UC patient’s disease in ~20–50% 
of cases36–40 and also after medical treatment. The MES includes 
only four grades to classify a wide variety and distribution of endo-
scopic inflammation. In this context, it may not reflect accurately 
the endoscopic response to specific drugs in clinical trials. For exam-
ple, a patient with pancolitis MES grade 2 at baseline who is treated 
with anti-tumour necrosis factor (anti-TNF) would be classified as a 
non-responder if control colonoscopy showed healing of the major 
part of the colon but persisting erosions in the rectum. There is 
a need to better characterize this therapeutic response, and taking 
disease extent into account can accommodate the collection of bet-
ter data to clarify the role of partial healing in the outcome of UC 
patients.
Table 3. Spearman correlations between clinical, biological, endoscopic and histological activity.
Mayo Endoscopic 
Subscore
Partial Mayo Score Fecal calprotectin (µg/g) C-reactive protein (mg/L) Geboes Score
Modified Score 0.945 0.622 0.725 0.266 0.657
p <0.001 p < 0.001 p < 0.001 p = 0.001 p < 0.001
Extended Modified Score 0.866 0.534 0.714 0.226 0.605
p < 0.001 p < 0.001 p < 0.001 p = 0.005 p < 0.001
Mayo Modified Endoscopic 
Score
0.887 0.535 0.730 0.238 0.615
p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001
Geboes Score 0.682 0.540 0.617 0.197
p < 0.001 p < 0.001 p < 0.001 p = 0.017
C-reactive protein (mg/L) 0.310 0.261 0.487
p < 0.001 p = 0.001 p < 0.001
Fecal calprotectin (µg/g) 0.669 0.555
p < 0.001 p < 0.001
Partial Mayo Score 0.548
p < 0.001
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Figure 1. MMES scores in patients with/without clinical, biological and histological activity.
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Partial MH has been previously assessed in Crohn’s disease (CD). 
In a post hoc analysis of the SONIC study,41 the endoscopic response 
(partial MH) was defined as a decrease from baseline in the Simple 
Endoscopic Score for Crohn’s Disease (SES-CD) or Crohn’s Disease 
Endoscopic Index of Severity (CDEIS) of at least 50%. The pres-
ence of endoscopic response at week 26 of treatment identified those 
most likely to be in corticosteroid-free clinical remission at week 50. 
Although the definition of MH is not yet validated, the post hoc analy-
sis of the SONIC study highlights the importance of considering also 
partial MH when assessing the response to any treatment. Despite the 
fact that, in the long term, complete MH is probably the most desirable 
endpoint, some treatments may result in a partial initial response, even 
though at a later stage a complete response may occur. Patients with 
such a treatment response should be recognized by careful endoscopic 
assessment in order not to misclassify them as non-responders as 
a result of using a less sensitive index to assess endoscopic activity, 
which may underestimate the response to the treatment.
Because of the need for a more accurate assessment of endoscopic 
activity in UC, two new endoscopic scores have been validated in the 
last 3 years. The first one is the UCEIS,29 which is an accurate index and 
has been demonstrated to capture 90% of the variability in the overall 
assessment of endoscopic severity but does not assess the endoscopic 
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extent and therefore cannot be used to identify partial MH. Indeed, as 
with the MES, only the most severely affected segment is evaluated, so 
partial MH cannot be picked up. The more recently developed UCCIS30 
is today the only endoscopic score for UC that considers endoscopic 
activity in all the segments of the colon. This score accounts for 80% 
of the variability in the endoscopic assessment of severity. However, 
this score requires the assessment of four endoscopic variables in the 
five segments of the colon followed by a complex calculation to render 
the final score. Therefore, despite its accuracy, the UCCIS may not be 
the easiest index to use in clinical practice. Moreover, most of the endo-
scopic procedures in the UC assessment are sigmoidoscopies and not 
complete colonoscopies, and no specific recommendation is given for 
the use of UCCIS in this context.
One of the advantages of MMES is that it relies on the maximal 
extent of inflammation. Therefore, in patients with proctitis or left-
sided colitis, sigmoidoscopy is normally enough to calculate the score. 
Moreover, its calculation is based on the widely known MES, not intro-
ducing new variables for the clinician. The fact that the MMES correlates 
well with clinical, biological and histological activity indexes indicates 
its possible clinical value in patient assessment and management.
One interesting finding of our study is the correlation of FC levels 
with the different grades of MMES, although in the multivariate anal-
ysis, after adjusting for the endoscopic extent, only the severity of the 
endoscopic activity was an independent predictor of FC levels. This 
has special relevance, as the literature on the utility of FC is scant and 
controversial. Roseth et al.42 found similar levels of FC among UC 
patients, regardless of their disease extent, whereas Diamanti et al.43 
showed that levels of FC were proportional to disease extent.
One of the strengths of this study is that all colonic samples were 
scored according to the GS34 and basal plasmacytosis since both 
have been demonstrated to have a prognostic value to predict clini-
cal relapse in UC patients.35 We have also demonstrated that MMES 
>0.8 can accurately predict active histological activity defined by GS 
≥3.1 and/or the presence of basal plasmacytosis.
Of note, patients classified in a specific grade of MES are further 
scored differently by the MMES according to disease extent. This 
might be a more accurate way of following up disease activity.
Our study has some limitations. First, the endoscopies were not 
video-recorded and therefore inter-observer agreement was not 
assessed. Second, the majority of patients were selected from the 
outpatient clinic and therefore a high proportion were in clinical and 
endoscopic remission. Third, 42 out of the 171 colonoscopies were 
incomplete, although these were only in patients with known distal 
colitis where the maximal extent of endoscopic activity was reached; 
moreover, this reflects daily clinical practice. Fourth, MMES does not 
reflect the impact of segmental colitis, since its calculation is done with 
the maximal extent of endoscopic activity. Finally, a multicentre pro-
spective cohort study with central reading will be necessary to validate 
the MMES. In addition, the accuracy of MMES in assessing response 
to specific treatments needs to be studied in more detail to explore its 
potential added value in clinical trials.
In conclusion, the MMES is a simple index to assess endoscopic 
activity in UC, taking into account the extent of mucosal inflamma-
tion and with an excellent correlation with clinical, biological and 
histological disease activity.
Further prospective studies are warranted to assess the clinical 
value of the MMES. Of note, a long-term trial should evaluate the 
predictive value of partial MH on long-term outcome.
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